IMCR — Immunocore Holdings Share News
0.000.00%
Last trade - 00:00- $1.54bn
- $1.05bn
- $400.02m
Brief: Medigene Sells Remaining Shares In Immunocore
Brief: Immunocore Announces That U.S. FDA And EMA Accept Biologics License Application And Marketing Authorization Application For Tebentafusp In Metastatic Uveal Melanoma
U.S. RESEARCH ROUNDUP-Adobe, Goodrx Holdings, PG&E
Immunocore Holdings PLC reports results for the quarter ended in June - Earnings Summary
Brief: Immunocore Reports Second Quarter 2021 Financial Results And Provides Business Update
Brief: Immunocore Presents Clinical Data Further Characterizing The Overall Survival Benefit Of Tebentafusp In Metastatic Uveal Melanoma At The 2021 American Society Of Clinical Oncology (Asco) Annual Meeting
Brief: Immunocore Reports Dosing Of First Patient With Immtav Bispecific Molecule For Chronic Hepatitis B
Immunocore Holdings PLC reports results for the quarter ended in March - Earnings Summary
Brief: Immunocore Holdings Reports Q1 Operating Loss Of 31.9 Million GBP
Brief: Immunocore Says Tebentafusp Showed Improvement In Overall Survival As First-Line Treatment In mUM
U.S. RESEARCH ROUNDUP- CytomX Therapeutics, Northern Trust, State Street
U.S. RESEARCH ROUNDUP- Altria Group, Honeywell, Travelzoo
Brief: Immunocore Sees Existing Cash, Equivalents Sufficient End Of 2022
Brief: Immunocore's Tebentafusp Granted Breakthrough Therapy Designation
Immunocore Holdings: Jumps 58% in market debut on Nasdaq
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Immunocore Announces Pricing Of Upsized IPO of 9.9 Mln ADS At $26 Per ADS